NASDAQ:KYTH - Kythera Biopharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.09 0.00 (0.00 %)
(As of 12/11/2018 11:11 AM ET)
Previous Close$0.09
Today's Range$0.09 - $0.09
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.

Receive KYTH News and Ratings via Email

Sign-up to receive the latest news and ratings for KYTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Current SymbolNASDAQ:KYTH
Previous Symbol


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Kythera Biopharmaceuticals (NASDAQ:KYTH) Frequently Asked Questions

What is Kythera Biopharmaceuticals' stock symbol?

Kythera Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KYTH."

How were Kythera Biopharmaceuticals' earnings last quarter?

Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.10) by $0.34. The biopharmaceutical company had revenue of $288 million for the quarter. View Kythera Biopharmaceuticals' Earnings History.

Has Kythera Biopharmaceuticals been receiving favorable news coverage?

Media coverage about KYTH stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kythera Biopharmaceuticals earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.

How do I buy shares of Kythera Biopharmaceuticals?

Shares of KYTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kythera Biopharmaceuticals' stock price today?

One share of KYTH stock can currently be purchased for approximately $0.09.

How can I contact Kythera Biopharmaceuticals?

Kythera Biopharmaceuticals' mailing address is 27200 Agoura Rd Ste 200, AGOURA HILLS, CA 91301-5127, United States. The biopharmaceutical company can be reached via phone at +1-818-5874500.

MarketBeat Community Rating for Kythera Biopharmaceuticals (NASDAQ KYTH)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Kythera Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KYTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KYTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by Staff

Featured Article: What is Cost of Debt?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel